Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.
Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer and founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer (TNBC).
Findings from the study, which were presented virtually during the 2020 ESMO Congress, revealed that patients who received the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) had a median progression-free survival of 5.6 months compared with 1.7 months with standard chemotherapy (HR, 0.41; 95% CI, 0.32-0.52; P < .0001).
This translates to a 59% reduction in the risk of disease progression or death with sacituzumab govitecan versus chemotherapy in this patient population, meeting the primary end point of the study, explains Bardia.
In April 2020, the FDA granted an accelerated approval to sacituzumab govitecan for the treatment of adult patients with metastatic TNBC who have received at least 2 prior therapies for metastatic disease.